Drugs / BLI5100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05890001 | Apr 2023 → Oct 2024 | esophagitis, gastroesophageal reflux disease | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT05587309 | Oct 2022 → Jun 2025 | esophagitis | Braintree Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT05587322 | Sep 2022 → Oct 2023 | gastroesophageal reflux disease | Braintree Laboratories | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BLI5100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05587322 ↗ |
| Route | Oral | “Orally via tablet” NCT05587309 ↗ |